DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Viread (Tenofovir Disoproxil Fumarate) - Published Studies

 


Nutrilib.com
A comprihensive source of nutritional information

Viread Related Published Studies

Well-designed clinical trials related to Viread (Tenofovir Disoproxil)

Lack of a significant drug interaction between raltegravir and tenofovir. [2008.09]

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. [2008.03]

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. [2008.01.01]

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. [2007.11.17]

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. [2007.11]

Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. [2007.07.01]

Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]

Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. [2007.05.25]

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. [2006.12.15]

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. [2006.11]

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. [2006.01.19]

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. [2006]

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. [2005.12.01]

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. [2005.07.22]

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. [2005.04]

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. [2004.11.01]

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. [2004.07.14]

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. [2004.06]

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. [2004.04.01]

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. [2004.03.01]

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. [2003.09.02]

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. [2003.05.01]

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. [2001.12.01]

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. [2001.10]

Well-designed clinical trials possibly related to Viread (Tenofovir Disoproxil)

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. [2008.10]

"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. [2008.07]

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. [2007.10.01]

Other research related to Viread (Tenofovir Disoproxil)

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. [2008.10.18]

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. [2008.08]

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. [2008.07.01]

Genetic basis of variation in tenofovir drug susceptibility in HIV-1. [2008.06.19]

Experience with tenofovir disoproxil fumarate for antiretroviral therapy. [2008.05]

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. [2008.04.15]

Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. [2008.04.01]

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. [2008.04]

The pharmacokinetics and viral activity of tenofovir in the male genital tract. [2008.03.01]

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. [2008.02]

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. [2008.02]

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. [2008.02]

Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. [2008.02]

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. [2008.02]

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis. [2008.01.01]

Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. [2008]

Predicting tenofovir concentration on the basis of renal factors determined by routine tests. [2007.11]

Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. [2007.10.01]

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. [2007.10]

Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. [2007.08.14]

Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen. [2007.07.19]

Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. [2007.07.11]

Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. [2007.06.19]

Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases. [2007.06.19]

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. [2007.06.19]

Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. [2007.06]

Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. [2007.03.30]

Tenofovir-induced kidney injury. [2007.03]

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. [2007.02]

Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? [2007.02]

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. [2007]

Acute renal failure after initiation of tenofovir disoproxil fumarate. [2007]

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. [2006.12.15]

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. [2006.12.01]

Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. [2006.12]

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. [2006.11.01]

Acquired Fanconi's syndrome associated with tenofovir therapy. [2006.11]

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. [2006.10.24]

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes: A 96-Week Analysis. [2006.10.12]

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. [2006.10.01]

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. [2006.10]

Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. [2006.10]

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. [2006.09]

Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. [2006.09]

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. [2006.08]

Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. [2006.08]

Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. [2006.08]

Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. [2006.07]

Tenofovir disoproxil fumarate for the treatment of HIV infection. [2006.06]

Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. [2006.05]

Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. [2006.05]

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons. [2006.04]

Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. [2006.04]

Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. [2006.04]

Serious renal impairment occurs rarely with use of tenofovir DF. [2006.03]

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. [2006.03]

Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. [2006.01.01]

Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. [2006.01]

Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. [2006]

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. [2006]

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. [2006]

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. [2006]

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. [2005.12]

Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. [2005.12]

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. [2005.12]

Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. [2005.11.18]

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. [2005.11.18]

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. [2005.10]

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. [2005.10]

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. [2005.09.15]

Tenofovir trials raise ethical issues. [2005.08]

Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. [2005.08]

Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature. [2005.08]

Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. [2005.07]

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008